How to buy Horizon Therapeutics Public Limited Company stock | $113.7

Horizon Therapeutics Public Limited Company is a drug manufacturers-general business based in the US. Horizon Therapeutics Public Limited Company shares (HZNP) are listed on the NASDAQ and all prices are listed in US Dollars. Horizon Therapeutics Public Limited Company employs 1,695 staff and has a trailing 12-month revenue of around 0.00.

Horizon Therapeutics Public Limited Company stock price (NASDAQ: HZNP)

Use our graph to track the performance of HZNP stocks over time.

Horizon Therapeutics Public Limited Company shares at a glance

• Key figures

Information last updated 2021-10-18.

Latest market close	$113.70
52-week range	$66.41 - $116.66
50-day moving average	$110.03
200-day moving average	$99.16
Wall St. target price	$134.75
PE ratio	51.2015
Dividend yield	N/A (0%)
Earnings per share (TTM)	$2.19

Buy Horizon Therapeutics Public Limited Company shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Horizon Therapeutics Public Limited Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Horizon Therapeutics Public Limited Company price performance over time

Historical closes compared with the close of $113.7 from 2021-10-20

1 week (2021-10-15)	1.45%
1 month (2021-09-22)	3.40%
3 months (2021-07-22)	13.62%
6 months (2021-04-22)	20.76%

1 year (2020-10-22)	49.49%
2 years (2019-10-22)	312.85%
3 years (2018-10-22)	490.96%
5 years (2016-10-21)	549.71%

Is Horizon Therapeutics Public Limited Company under- or over-valued?

Valuing Horizon Therapeutics Public Limited Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Horizon Therapeutics Public Limited Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Horizon Therapeutics Public Limited Company's P/E ratio

Horizon Therapeutics Public Limited Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Horizon Therapeutics Public Limited Company shares trade at around 51x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Horizon Therapeutics Public Limited Company's PEG ratio

Horizon Therapeutics Public Limited Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Horizon Therapeutics Public Limited Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Horizon Therapeutics Public Limited Company's EBITDA

Horizon Therapeutics Public Limited Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $581.9 million.

The EBITDA is a measure of a Horizon Therapeutics Public Limited Company's overall financial performance and is widely used to measure a its profitability.

Horizon Therapeutics Public Limited Company financials

Revenue TTM	$2.6 billion
Operating margin TTM	20.9%
Gross profit TTM	$1.7 billion
Return on assets TTM	5.24%
Return on equity TTM	16.1%
Profit margin	20.27%
Book value	$18.05
Market capitalisation	$25.3 billion

TTM: trailing 12 months

Shorting Horizon Therapeutics Public Limited Company shares

There are currently 3.7 million Horizon Therapeutics Public Limited Company shares held short by investors – that's known as Horizon Therapeutics Public Limited Company's "short interest". This figure is 5.8% down from 4.0 million last month.

There are a few different ways that this level of interest in shorting Horizon Therapeutics Public Limited Company shares can be evaluated.

Horizon Therapeutics Public Limited Company's "short interest ratio" (SIR)

Horizon Therapeutics Public Limited Company's "short interest ratio" (SIR) is the quantity of Horizon Therapeutics Public Limited Company shares currently shorted divided by the average quantity of Horizon Therapeutics Public Limited Company shares traded daily (recently around 1.0 million). Horizon Therapeutics Public Limited Company's SIR currently stands at 3.68. In other words for every 100,000 Horizon Therapeutics Public Limited Company shares traded daily on the market, roughly 3680 shares are currently held short.

However Horizon Therapeutics Public Limited Company's short interest can also be evaluated against the total number of Horizon Therapeutics Public Limited Company shares, or, against the total number of tradable Horizon Therapeutics Public Limited Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Horizon Therapeutics Public Limited Company's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Horizon Therapeutics Public Limited Company shares in existence, roughly 20 shares are currently held short) or 0.0168% of the tradable shares (for every 100,000 tradable Horizon Therapeutics Public Limited Company shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Horizon Therapeutics Public Limited Company.

Find out more about how you can short Horizon Therapeutics Public Limited Company stock.

Horizon Therapeutics Public Limited Company share dividends

We're not expecting Horizon Therapeutics Public Limited Company to pay a dividend over the next 12 months.

Horizon Therapeutics Public Limited Company share price volatility

Over the last 12 months, Horizon Therapeutics Public Limited Company's shares have ranged in value from as little as $66.41 up to $116.66. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Horizon Therapeutics Public Limited Company's is 1.0434. This would suggest that Horizon Therapeutics Public Limited Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Horizon Therapeutics Public Limited Company overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019.

Frequently asked questions

What percentage of Horizon Therapeutics Public Limited Company is owned by insiders or institutions?
Currently 1.026% of Horizon Therapeutics Public Limited Company shares are held by insiders and 92.131% by institutions. How many people work for Horizon Therapeutics Public Limited Company?
Latest data suggests 1,695 work at Horizon Therapeutics Public Limited Company. When does the fiscal year end for Horizon Therapeutics Public Limited Company?
Horizon Therapeutics Public Limited Company's fiscal year ends in December. Where is Horizon Therapeutics Public Limited Company based?
Horizon Therapeutics Public Limited Company's address is: Connaught House, Dublin, Ireland, 4 What is Horizon Therapeutics Public Limited Company's ISIN number?
Horizon Therapeutics Public Limited Company's international securities identification number is: IE00BQPVQZ61 What is Horizon Therapeutics Public Limited Company's CUSIP number?
Horizon Therapeutics Public Limited Company's Committee on Uniform Securities Identification Procedures number is: 44047T109